Jeb KeiperFounder

United States - Cambridge, Massachusetts,

Jeb Keiper is the Chief Executive Officer of Nimbus Therapeutics, a biotechnology company discovering novel medicines against important, but previously inaccessible drug targets. Follow me @JebKeiper

Mr. Keiper joined Nimbus in 2014 and initially served as Nimbus’ Chief Business Officer, and helped set the strategic direction of the company. Between 2014 and 2018, Nimbus brought in over $775 million of partnership and financing into the company, including the Series B financing in March 2015, the sale of Nimbus’ clinical NASH program to Gilead in May 2016 for $400 million upfront, the strategic immunology alliance with Celgene announced in October 2017, and a round of private expansion capital in 2018. Mr. Keiper was also appointed Chief Financial Officer in 2017.

In June 2018, Jeb was elected as an independent director to the board of Cardurion Pharmaceuticals, LLC, a clinical-stage cardiovascular diseases company based in Cambridge, MA.

Prior to Nimbus, Jeb was VP of Business Development at GSK Oncology and spent a decade at GSK in various BD leadership roles. Jeb led the oncology portion of the GSK-Novartis 3-business swap for $16b announced in April 2014.

Prior to GSK, Jeb was a consultant at McKinsey and worked in BD at TransForm Pharmaceuticals. Jeb began his career at Pfizer R&D as a bench chemist. He received four degrees from MIT; one in Chemistry, two in Chemical Engineering, and an MBA from MIT Sloan.